Objective: Well-differentiated papillary adenocarcinoma of the lung (G1 cancer cells) is difficult to distinguish from benign bronchial columnar epithelial cells with reactive atypia (benign cells) in many cases because nuclear atypia is mild. We focused on the 3-dimensional presence of nuclei in cell smears. Several images focused on the nucleus were acquired, and the nuclear luminance was measured and analyzed. Study Design: One hundred G1 cancer cells and benign cells (nuclei), respectively, were selected from those on a bronchial brushing preparation for cytology. Images of 41 layers were acquired at 0.25-µm intervals in each cell, and the nuclear luminance was measured (a total of 8,400 images). Results: There were more focus positions in the G1 cancer cell nuclei, showing a 3-dimensional nucleus, compared to benign cells, and the 3-dimensional variation in the coefficient of variation (CV) of nuclear luminance at the focus position was smaller in G1 cancer than in benign cells, showing a significant difference. Conclusion: The G1 cancer cells’ nuclear structure was more 3-dimensional, and the chromatin distribution was homogeneous. The three-dimensional variation in the nuclear luminance CV could be numerically presented, which might be an objective index for cancer diagnosis.

1.
Araki K, Fukuda S, Arie K: The efficacy of intraoperative cytology in patients with lung tumor. J Jpn Soc Clin Cytol 2008;47:81–85.
2.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
3.
Ueno T, Iwasaki A, Yamamoto S, Shiraishi T, Hiratsuka M, Yoshinaga Y, Shirakusa T: Clinical study of resected lung adenocarcinoma 10 mm or less in diamete. JACSURG 2007;21:776–783.
4.
Washiya K, Konno T, Ishii A, Tokairin T, Ono I: Evaluation of the urine cytodiagnosis using simple method of measuring nucleus brightness histogram. J Jpn Soc Clin Cytol 2008;47:154–155.
5.
Rajagopalan H, Lengauer C: Aneuploidy and cancer. Nature 2004;432:338–341.
6.
Sato T, Miura T, Nakano K, Nozaka H, Sato T, Ishikawa T, Chiba M, Kanazawa Y, Kizawa C, Hasegawa S, Yasujima M: Reliable differential diagnosis between osteosarcoma and regenerative bone cells in rats through simultaneous analysis of nuclear DNA content and size. Anal Quant Cytol Histol 2000;22:327–332.
7.
Volm M, Mattern J, Sonka M, Vogt-Schaden M, Wayss K: DNA distribution in non-small-cell lung carcinomas and its relationship to clinical behavior. Cytometry 1985;6:348–356.
8.
Niimi H, Kaneko C, Niimi M, Shamoto M: Consecutive observation of Papanicolaou-stained cells by scanning and transmission electron microscopy. J Jpn Soc Clin Cytol 1994;33:43–52.
9.
Tsukinoki K, Watanabe Y: Analysis of apoptosis by confocal laser scanning microscopy based on three-dimensional images. Jpn J Oral Biol 1997;39:223–240.
10.
Yamamoto K, Horiguchi H, Kamma H, Ogata T, Fukazawa M, Ikezawa T, Inage Y, Akazawa E, Mitsui K, Hori M: The effect of nuclear DNA content in nuclear atypia and clinicopathological factors in non-small cell lung carcinoma. J Jpn Soc Clin Cytol 1993;32:846–852.
11.
Harashima S, Tsuzuku M: Evaluation of cytological findings added to three-dimensional nuclear atypia of breast diseases using multivariate statistical analysis. J Jpn Soc Clin Cytol 1998;37:13–20.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.